Joseph Caldarella - Bristol-Myers Squibb Senior Vice President Corporate Controller

President

Mr. Joseph C. Caldarella is no longer Senior Vice President, Corporationrationrate Controller of the company effective March 30, 2018. From 2005 to 2010, Vice President and Corporationrationrate Controller. He was 1998 to 2005 Vice President, Finance, Pharmaceutical Research Institute, a division of the Company. since 2010.
Age 61
Tenure 14 years
Phone212-546-4000
Webhttp://www.bms.com

Similar Executives

Showing other executives

PRESIDENT Age

Gregory DowellSummit Hotel Properties
52
Greg DowellSummit Hotel Properties
50
Margo ManningDave Busters Entertainment
52
David GordonThe Cheesecake Factory
59
Elizabeth JacksonKVH Industries
46
Rachael RothmanPlaya Hotels Resorts
47
Paul BaldassariFlex
N/A
Max ByfuglinThe Cheesecake Factory
70
KEVIN KESSELFlex
N/A
Joe DeprosperoDave Busters Entertainment
43
Ken LokeKVH Industries
N/A
Jordan VargasKVH Industries
N/A
Scott BowmanDave Busters Entertainment
51
Francois BarbierFlex
57
Matthew ClarkThe Cheesecake Factory
54
Michael HartungFlex
55
Michael PlunkettDave Busters Entertainment
66
William ConklingSummit Hotel Properties
48
Paul RuizSummit Hotel Properties
58
John CarlsonFlex
N/A
Scarlett MayThe Cheesecake Factory
58
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people. Bristol Myers Squibb [BMYMP] is a Pink Sheet which is traded between brokers over the counter.

Bristol-Myers Squibb Leadership Team

Elected by the shareholders, the Bristol-Myers Squibb's board of directors comprises two types of representatives: Bristol-Myers Squibb inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol-Myers. The board's role is to monitor Bristol-Myers Squibb's management team and ensure that shareholders' interests are well served. Bristol-Myers Squibb's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol-Myers Squibb's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ann Powell, Chief Human Resource Officer, Senior Vice President
Togo West, Independent Director
Karen Vousden, Director
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics Officer
Alan Lacy, Independent Director
Robert Bertolini, Independent Director
Jose Baselga, Independent Director
Charles Bancroft, CFO, Executive Vice President
Gerald Storch, Independent Director
Louis Schmukler, President - Global Manufacturing and Supply
Michael Grobstein, Independent Director
Christopher Boerner, Executive Vice President and Chief Commercial Officer
John Elicker, Senior Vice President - Public Affairs and Investor Relations
Anne Nielsen, Senior Vice President Chief Compliance and Ethics Officer
Karen Santiago, Senior Vice President Controller
Giovanni Caforio, COO, Director
Vicki Sato, Independent Director
Emmanuel Blin, Senior Vice President Chief Strategy Officer
Joseph Caldarella, Senior Vice President Corporate Controller
Laurie Glimcher, Independent Director
Murdo Gordon, Executive Vice President Chief Commercial Officer
Lamberto Andreotti, CEO, Director
Thomas Lynch, Independent Director
Dinesh Paliwal, Independent Director
Lewis Campbell, Independent Director
Theodore Samuels, Independent Director
Samuel Moed, Senior Vice President - Strategic Planning and Analysis
Matthew Emmens, Independent Director
Ann Judge, Senior Vice President - Global Human Resources
Sandra Leung, General Counsel, Corporate Secretary
Paul Autenried, Senior Vice President - Enterprise Services, CIO
Francis Cuss, Executive Vice President Chief Scientific Officer
Paul Biondi, Senior Vice President Head - Business Development
Peter Arduini, Independent Director

Bristol-Myers Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bristol-Myers Squibb a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Bristol-Myers Squibb

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol-Myers Squibb position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to AmerisourceBergen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AmerisourceBergen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AmerisourceBergen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AmerisourceBergen to buy it.
The correlation of AmerisourceBergen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AmerisourceBergen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AmerisourceBergen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AmerisourceBergen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Other Consideration for investing in Bristol-Myers Pink Sheet

If you are still planning to invest in Bristol-Myers Squibb check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bristol-Myers Squibb's history and understand the potential risks before investing.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities